Diabetes mellitus type 2

Indication for Nateglinide

Population group: Suitable for both men and women, only adults (18 - 65 years old)

Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.

For this indication, competent medicine agencies globally authorize below treatments:

180-540 mg in 3 divided doses daily

Route of admnistration


Defined daily dose

180 - 540 mg

Dosage regimen

From 60 To 180 mg 3 time(s) per day every day

Detailed description

Nateglinide should be taken within 1 to 30 minutes before meals (usually breakfast, lunch and dinner).

The dosage of nateglinide should be determined by the physician according to the patient’s requirements.

The recommended starting dose is 60 mg three times daily before meals, particularly in patients who are near goal HbA1c. This may be increased to 120 mg three times daily.

Dose adjustments should be based on periodic glycosylated haemoglobin (HbA1c) measurements. Since the primary therapeutic effect of nateglinide is to reduce mealtime glucose (a contributor to HbA1c), the therapeutic response to nateglinide may also be monitored with 1-2 hour post-meal glucose.

The recommended maximum daily dose is 180 mg three times daily to be taken before the three main meals.

Dosage considerations

Nateglinide should be taken within 1 to 30 minutes before meals.

Active ingredient

Nateglinide is an amino acid (phenylalanine) derivative, which is chemically and pharmacologically distinct from other antidiabetic agents. Nateglinide is a rapid, short-acting oral insulin secretagogue. Its effect is dependent on functioning beta cells in the pancreas islets.

Read more about Nateglinide

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner